Leflunomide Tablet, Film Coated
Product Images NDC 70710-1157

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Leflunomide (NDC 70710-1157). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Zydus Pharmaceuticals (usa) Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

F1c37612 9041 490e 93e9 30e838015b4a 01

Chemical structure of leflunomide showing its molecular components including an oxazole ring, amide group, aromatic ring, and trifluoromethyl group.*

FDA Label Image

F1c37612 9041 490e 93e9 30e838015b4a 02

Chemical structure diagram of teriflunomide, labeled A77 1726, which is related to the active ingredient leflunomide.*

FDA Label Image

F1c37612 9041 490e 93e9 30e838015b4a 03

A bar chart titled '% ACR 20 Responder at Endpoint' showing response percentages across three trials (Trial 1: 12 months, Trial 2: 6 months, Trial 3: 12 months) for different treatments: Leflunomide (L), Methotrexate (M), Placebo (P), and Sulfasalazine (S). The vertical axis represents percentage from -20 to 70%, and bars indicate measured response rates for each treatment in the trials.*

FDA Label Image

F1c37612 9041 490e 93e9 30e838015b4a 04

A line graph titled "Trial 1 ACR Responders Over Time*" showing percentage of responders on the y-axis and time in months on the x-axis. It compares response rates over 12 months for three groups labeled PL (placebo), MTX (methotrexate), and LEF (leflunomide). The LEF group shows the highest percentage of responders throughout the study period.*

FDA Label Image

F1c37612 9041 490e 93e9 30e838015b4a 05

A bar chart titled 'Change in Sharp Score' depicting data from three clinical trials over 6 to 12 months. The chart compares progression scores for leflunomide (L), methotrexate (M), sulfasalazine (S), and placebo (P). The vertical axis represents progression, and the horizontal axis shows results by trial and treatment, with values noted above each bar.*

FDA Label Image

F1c37612 9041 490e 93e9 30e838015b4a 06

A bar chart titled 'Change in Functional Ability Measure' showing improvement values for different trials and treatments including Leflunomide, Methotrexate, Placebo, and Sulfasalazine, measured by the HAQ Disability Index over 6 and 12 months.*

FDA Label Image

F1c37612 9041 490e 93e9 30e838015b4a 07

Label for leflunomide tablets, USP 10 mg film-coated oral tablets by Zydus Pharmaceuticals (USA) Inc. The label indicates a package size of 30 tablets and displays two images of the tablet imprinted with '11' and '57'. Manufacturing is noted by Cadila Healthcare Ltd., India, with distribution by Zydus Pharmaceuticals (USA) Inc. Storage and handling instructions are also included.*

FDA Label Image

F1c37612 9041 490e 93e9 30e838015b4a 08

Label for Leflunomide Tablets USP 20 mg film-coated oral tablets by Zydus Pharmaceuticals (USA) Inc. The label specifies 30 tablets per container, includes the NDC 70710-1158-3, and notes manufacturing by Cadila Healthcare Ltd., India, with distribution by Zydus Pharmaceuticals in Pennington, NJ.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.